Pieris Pharmaceuticals To Present at H.C. Wainwright Global Investment Conference

Rhea-AI Summary

Pieris Pharmaceuticals (NASDAQ:PIRS) will present at the H.C. Wainwright Global Investment Conference on May 25, 2022, at 9:30 AM EDT. The presentation will be available via webcast at the provided link. The company focuses on developing innovative biotherapeutics using its unique Anticalin technology platform, targeting respiratory diseases and cancer. Pieris aims to create inhalable Anticalin proteins for respiratory issues and bispecifics for immuno-oncology, showcasing its commitment to delivering superior clinical outcomes.

BOSTON, MA / ACCESSWIRE / May 18, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that management is scheduled to present at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022 at 9:30 AM EDT. A webcast of the company's presentation will be available at this link.

About Pieris Pharmaceuticals:

Pieris is a clinical-stage biotechnology company that combines leading protein engineering capabilities and deep understanding into molecular drivers of disease to develop medicines that drive local biology to produce superior clinical outcomes for patients. Our pipeline includes inhalable Anticalin proteins to treat respiratory diseases and locally-activated bispecifics for immuno-oncology. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by respiratory and immuno-oncology focused partnerships with leading pharmaceutical companies. For more information, visit www.pieris.com.

Investor Relations Contact:
Pieris Pharmaceuticals, Inc.
Maria Kelman
Executive Director, Investor Relations
+1 857 362 9635
kelman@pieris.com

SOURCE: Pieris Pharmaceuticals, Inc.

View source version on accesswire.com:
https://www.accesswire.com/701810/Pieris-Pharmaceuticals-To-Present-at-HC-Wainwright-Global-Investment-Conference

FAQ

What is Pieris Pharmaceuticals presenting at the H.C. Wainwright Global Investment Conference?

Pieris Pharmaceuticals will present its innovative biotherapeutics and Anticalin technology on May 25, 2022.

When is Pieris Pharmaceuticals' presentation scheduled at the conference?

The presentation is scheduled for May 25, 2022, at 9:30 AM EDT.

Where can I watch the Pieris Pharmaceuticals presentation?

The presentation will be available via webcast at the link provided in the press release.

What is the focus of Pieris Pharmaceuticals' pipeline?

Pieris focuses on developing inhalable Anticalin proteins for respiratory diseases and locally-activated bispecifics for immuno-oncology.

What technology does Pieris Pharmaceuticals utilize for its biotherapeutics?

Pieris Pharmaceuticals utilizes its proprietary Anticalin technology platform for developing its biotherapeutics.